Study guide

Community care, Item 715 and CTG medicines

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Community care, Item 715 and CTG medicines

Key Takeaways Explain This Topic AI

Item 715 and CTG registration are separate processes.

CTG access is not conditional on completing an Item 715 assessment.

Rheumatic-heart-disease prophylaxis duration depends on disease severity and individual risk.

Last updated: October 2026

Aboriginal Community Controlled Health Organisations (ACCHOs)

Aboriginal Community Controlled Health Organisations (ACCHOs) represent the gold standard of primary healthcare delivery for First Nations Australians. The first ACCHO was established in Redfern, Sydney, in 1971 in response to widespread discrimination and lack of accessible primary healthcare.

Governance Model : An ACCHO is an incorporated organisation initiated, governed, and operated by the local Aboriginal community through an elected Board of Directors.

Comprehensive Primary Health Care (CPHC) : ACCHOs deliver holistic care that encompasses clinical general practice, chronic disease management, dental care, maternal-child health, mental health and social-emotional wellbeing, substance rehabilitation, aged care, and transport services.

ACCHOs: Community governance and culturally safe care can improve access and continuity. Partner with the service chosen by the patient, and recognise local strengths and needs rather than assuming one service model fits every community.

Australian Primary Care Initiatives: MBS Item 715 & PBS Co-Payment

The Commonwealth Government has established targeted Medicare and Pharmaceutical Benefits Scheme (PBS) mechanisms to enhance primary prevention and treatment adherence for First Nations Australians.

Medicare MBS Item 715: Health Assessment for Aboriginal and Torres Strait Islander People

Item 715: Available to eligible Aboriginal and Torres Strait Islander people of all ages, once every nine months under the descriptor. Tailor the assessment to age, risks and preferences; it is not a compulsory identical pathology panel for every child and adult.

Child assessment: Infants and children aged 0 to 14 years.

Adult assessment: Adults aged 15 to 54 years.

Older person assessment: Adults aged ≥ 55 years \ge 55\text{ years} ≥ 55 years .

Clinical Components : A structured, comprehensive annual review encompassing:

Medical history, family history, and lifestyle factors (nutrition, physical activity, smoking, alcohol, substance use).

Physical examination: Blood pressure, BMI, waist circumference, oral health, vision, and ear examination with otoscopy.

Pathology screening: Cardiovascular lipid profile, blood glucose / HbA1c, and renal function (serum eGFR and urine albumin-to-creatinine ratio [ACR]).

Immunisation status review and routine update.

Assessment of social, emotional, and cultural wellbeing.

Secondary Benefits Unlocked by Item 715 :

Unlocks access to MBS Items 81300 to 81360 , which provide up to 5 Medicare-subsidized individual allied health consultations per calendar year (e.g., podiatry, physiotherapy, exercise physiology, dietetics, diabetes education, psychology).

Unlocks follow-up services provided by Aboriginal Health Workers and practice nurses under MBS Item 10987.

The PBS Co-Payment Measure (Closing the Gap)

Purpose : Alleviates financial barriers to medication adherence for First Nations patients managing chronic medical conditions.

CTG eligibility: The person self-identifies as Aboriginal/Torres Strait Islander, is enrolled in Medicare, would have setbacks without the medicine and is unlikely to continue treatment without cost help. Obtain consent and register through HPOS using an eligible PBS prescriber/health practitioner or delegate. Item 715 is not a prerequisite, and registration need not be repeated after moving clinics.

Financial Entitlement :

General patients (non-concession cardholders) pay only the concessional co-payment rate for PBS-listed medicines.

Concession cardholders receive their PBS-listed medicines completely free of charge ($0 co-payment).

Culturally Safe Communication & Consultation Practice

Effective communication with Aboriginal and Torres Strait Islander patients requires adapting conventional Western consultation styles to foster trust, rapport, and mutual respect.

1. Clinical Yarning

Clinical yarning is an evidence-based communication framework that combines traditional First Nations storytelling with biomedical clinical consultation:

Respect the person’s pace and preferences. Allow time to reflect, use an interpreter where needed, and ask whom they want involved. Family/community strengths can support care, but the patient remains central to consent and confidentiality.

Diagnostic Yarn : The clinician invites the patient to tell their health story in their own words, exploring the patient's illness perspective, social context, and physical symptoms through open-ended, non-judgmental discussion.

Management Yarn : The clinician and patient collaboratively interpret clinical findings and negotiate a shared management plan that aligns with the patient's cultural responsibilities, family priorities, and living circumstances.

2. Respecting Silence

In First Nations communication, silence is an active, positive, and purposeful component of dialogue. Pauses allow thoughtful reflection, emotional processing, and respect for the conversation. Clinicians must:

Remain comfortable with extended pauses (10 to 30 seconds).

Resist the urge to interrupt, fill the silence, or rephrase the question prematurely.

Avoid interpreting silence as incomprehension, disinterest, or passivity.

3. Non-Verbal Communication & Eye Contact

Direct, continuous, or piercing eye contact can be perceived as confrontational, invasive, or disrespectful, particularly when interacting with Elders or members of the opposite sex.

Communication preferences: Ask what helps the person feel comfortable and follow their cues. Eye contact, silence, language, kinship involvement and decision-making preferences vary between people and communities; cultural safety must not become a fixed stereotype.

4. Involving Kinship Networks, Family & Elders

Family members (aunties, grandmothers, partners, siblings) frequently accompany patients and play a central role in health decision-making.

Clinicians should actively welcome family members into consultations and obtain the patient's consent to involve trusted family in treatment discussions and discharge planning.

5. Partnering with Aboriginal Health Workers & Liaison Officers

Aboriginal Health Workers (AHWs) & Aboriginal Health Practitioners (AHPs) : AHPs are registered healthcare professionals under AHPRA with specialized clinical training. They provide direct clinical care, perform health assessments, administer medications, and serve as invaluable cultural brokers.

Aboriginal Hospital Liaison Officers (AHLOs) : Hospital-based professionals who provide emotional support, assist with communication between medical teams and families, facilitate discharge planning, and help reduce rates of discharge against medical advice.

Clinical comparison: High-Burden Conditions & Management Protocols

ARF/RHD : Etiology & Risk Context: GAS-associated immune disease; Key Clinical Screening / Diagnostic Feature: Assess with the current Australian diagnostic criteria and echocardiography; Evidence-Based Prevention & Management: Benzathine benzylpenicillin usually four-weekly; duration depends on ARF history and RHD severity, not one universal ten-year rule

Rheumatic Heart Disease (RHD) : Etiology & Risk Context: Cumulative permanent valve scarring from recurrent ARF attacks; Key Clinical Screening / Diagnostic Feature: Echocardiography screening (mitral regurgitation/stenosis, aortic regurgitation); Evidence-Based Prevention & Management: Register on State/Territory RHD register; regular echocardiography; secondary penicillin prophylaxis

Trachoma : Etiology & Risk Context: Recurrent ocular Chlamydia trachomatis infection in remote communities; Key Clinical Screening / Diagnostic Feature: Follicular conjunctivitis in children; trichiasis and corneal opacification in adults; Evidence-Based Prevention & Management: WHO SAFE strategy; single-dose oral azithromycin ( 20 mg/kg 20\text{ mg/kg} 20 mg/kg up to 1 g 1\text{ g} 1 g ) for cases and community contacts

Otitis in high-risk children: Australian First Nations guidance uses persistent ear discharge with a perforation for at least two weeks to define CSOM. Arrange ear toilet, appropriate topical treatment, hearing assessment and follow-up rather than waiting six weeks.

Chronic Kidney Disease (CKD) : Etiology & Risk Context: Diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis; Key Clinical Screening / Diagnostic Feature: Annual urine albumin-to-creatinine ratio (ACR) and eGFR screening via MBS Item 715; Evidence-Based Prevention & Management: SGLT2 inhibitors; ACE inhibitors or ARBs; aggressive BP control ( < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg ); pre-dialysis pathway

Type 2 Diabetes Mellitus : Etiology & Risk Context: Insulin resistance, metabolic syndrome, social determinants; Key Clinical Screening / Diagnostic Feature: Annual HbA1c screening; early onset in youth and young adults; Evidence-Based Prevention & Management: Lifestyle support; metformin; SGLT2 inhibitors and GLP-1 receptor agonists; PBS Co-payment access

Primary references (checked 7 October 2026): 2025 Australian ARF/RHD guideline ; CTG eligibility .